

Cooper Jeffrey H
Form 4
March 04, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Cooper Jeffrey H

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
02/29/2008

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
SVP, Chief Financial Officer

C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

NOVATO, CA 94949

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/29/2008		M		2,084	A	\$ 8.1
					3,089		
Common Stock	02/29/2008		M		1,042	A	\$ 7.76
					4,131		
Common Stock	02/29/2008		M		1,250	A	\$ 5.15
					5,381		
Common Stock	02/29/2008		M		19,999	A	\$ 6.13
					25,380		
	02/29/2008		M		31,250	A	
					56,630		

Edgar Filing: Cooper Jeffrey H - Form 4

Common Stock					\$ 11.74		
Common Stock	02/29/2008	S	1,100	D	\$ 37.53	55,530	D
Common Stock	02/29/2008	S	400	D	\$ 37.55	55,130	D
Common Stock	02/29/2008	S	7,400	D	\$ 37.56	47,730	D
Common Stock	02/29/2008	S	8,900	D	\$ 37.57	38,830	D
Common Stock	02/29/2008	S	3,350	D	\$ 37.58	35,480	D
Common Stock	02/29/2008	S	525	D	\$ 37.59	34,955	D
Common Stock	02/29/2008	S	10,800	D	\$ 37.6	24,155	D
Common Stock	02/29/2008	S	1,666	D	\$ 37.61	22,489	D
Common Stock	02/29/2008	S	1,208	D	\$ 37.62	21,281	D
Common Stock	02/29/2008	S	200	D	\$ 37.63	21,081	D
Common Stock	02/29/2008	S	33	D	\$ 37.64	21,048	D
Common Stock	02/29/2008	S	2,381	D	\$ 37.65	18,667	D
Common Stock	02/29/2008	S	700	D	\$ 37.66	17,967	D
Common Stock	02/29/2008	S	900	D	\$ 37.67	17,067	D
Common Stock	02/29/2008	S	1,900	D	\$ 37.68	15,167	D
Common Stock	02/29/2008	S	1,017	D	\$ 37.69	14,150	D
Common Stock	02/29/2008	S	883	D	\$ 37.7	13,267	D
Common Stock	02/29/2008	S	557	D	\$ 37.72	12,710	D
Common Stock	02/29/2008	S	100	D	\$ 37.73	12,610	D
	02/29/2008	S	100	D		12,510	D

Edgar Filing: Cooper Jeffrey H - Form 4

Common Stock					\$ 37.74		
Common Stock	02/29/2008	S	1,400	D	\$ 37.75	11,110	D
Common Stock	02/29/2008	S	1,100	D	\$ 37.76	10,010	D
Common Stock	02/29/2008	S	2,300	D	\$ 37.77	7,710	D
Common Stock	02/29/2008	S	500	D	\$ 37.78	7,210	D
Common Stock	02/29/2008	S	300	D	\$ 37.79	6,910	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 8.1	02/29/2008		M	2,084	04/06/2004 ⁽¹⁾	10/05/2013	Common Stock	2,084
Stock Option (right to buy)	\$ 7.76	02/29/2008		M	1,042	06/30/2004 ⁽²⁾	12/30/2013	Common Stock	1,042
Stock Option (right to buy)	\$ 5.15	02/29/2008		M	1,250	02/19/2005 ⁽³⁾	08/18/2014	Common Stock	1,250
	\$ 6.13	02/29/2008		M	19,999	07/07/2005 ⁽⁴⁾	01/07/2015		19,999

Stock
Option
(right to
buy)

Common
Stock

Stock
Option
(right to
buy)

\$ 11.74

02/29/2008

M

31,250

07/13/2006⁽⁵⁾

01/13/2016

Common
Stock

31,250

Reporting Owners

Reporting Owner Name / Address

Relationships

Director

10% Owner

Officer

Other

Cooper Jeffrey H
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949

SVP, Chief Financial Officer

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact

03/04/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Original option grant vested 6/48ths on April 6, 2004 and 1/48th on the 6th of every month thereafter.
- (2) Original option grant vested 6/48ths on June 30, 2004 and 1/48th on the 30th of every month thereafter.
- (3) Original option grant vested 6/48ths on February 19, 2005 and 1/48th on the 19th of every month thereafter.
- (4) Original option grant vested 6/48ths on July 7, 2005 and 1/48th on the 7th of every month thereafter.
- (5) Original option grant vested 6/48ths on July 13, 2006 and 1/48th on the 13th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.